Format

Send to

Choose Destination
Immunol Allergy Clin North Am. 2018 Aug;38(3):469-481. doi: 10.1016/j.iac.2018.04.002. Epub 2018 Jun 9.

Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.

Author information

1
Division of Gastroenterology, Hepatology, and Endoscopy, Harvard Medical School, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address: mjhamilton@bwh.harvard.edu.

Abstract

Patients who present with typical features of mast cell activation with laboratory confirmation and without evidence of a clonal mast cell disorder or other medical condition should be initiated on medical treatment to block mast cells and their mediators. If a major response is achieved, a diagnosis of nonclonal mast cell activation syndrome (NC-MCAS) is likely and treatment should be optimized, including management of any associated conditions. In this review, the latest evidence with regard to the diagnosis and treatment of NC-MCAS is presented.

KEYWORDS:

Flushing; Histamine; Mast cell; Mast cell activation syndrome; Mastocytosis; Prostaglandin; Tryptase

PMID:
30007464
PMCID:
PMC6049091
[Available on 2019-08-01]
DOI:
10.1016/j.iac.2018.04.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center